The UK and US have secured a significant bilateral deal that will preserve no duties on British pharmaceutical shipments entering the US market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to boost spending on medicines through the National Health Service (NHS). This pledge guarantees that duties on these key exports will be held at zero for a duration of the next three years.
This agreement is in response to previous threats to hike import taxes on branded drug products, with figures mentioned up to 100%.
"This arrangement with the Britain strengthens the worldwide climate for new treatments and introduces long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release said.
Trade Importance
Drugs constitute one of the the United Kingdom's biggest export categories to the US, which is easily the biggest destination for leading UK drugmakers.
Trade data show that in the year leading up to last September, the UK exported drugs valued at billions to the US. This figure represented a significant portion of all goods exports in that span.
"This deal safeguards jobs, stimulates investment and paves the way for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary stated.
Detailed NHS Changes
The deal includes several specific pledges from the British government:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new medicines to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to raise overall NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be capped at fifteen percent. In the past, repayments topped twenty percent.
Recent Tensions
The deal comes amid a long-running dispute between the sector and the UK government over spending levels and regulatory access.
This friction were heightened by claims that US patients were paying a premium for the equivalent treatments than people in the other developed nations.
In recent months, several major drug company projects in the UK have been paused or abandoned, while major funding commitments have been announced toward American operations.
The Science Minister acknowledged that the NHS had to spend more on drugs, noting that its spending on drugs had shrunk as a percentage of its total funding over the last ten years.
